YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
CytomX Therapeutics Inc. Varsetatug masetecan ("Varseta-M") Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in…
CytomX Therapeutics Inc. Varsetatug masetecan ("Varseta-M") Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in…
CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-activated bispecific cancer therapies. By…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Regeneron Pharmaceuticals (REGN) has been back in focus after expanding its cancer therapy partners…
Regeneron Pharmaceuticals, Inc. REGN expanded its licensing and collaboration agreement with clinical-stage, oncology-focused biopharmaceutical company CytomX Therapeutics, Inc. CTMX. Both companies have expanded their collaboration to dev…
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the afternoon session after the company announced an expanded cancer therapy collaboration and reported positive clinical trial data for one of its treatments.…
CytomX Therapeutics Inc. - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $37 million target…
[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell…
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following i…
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.3 per share a year ago. These figures are adjusted for non-recurring…
When looking for investments in the healthcare space, smaller companies tend to be more alluring. They can be working on drugs or releasing drugs with breakthrough potential. Those companies also carry a lot of risk, however, because there…
CytomX Therapeutics (NASDAQ:CTMX) is one of the best healthcare penny stocks to buy according to hedge funds. On March 24, analysts at Jefferies reiterated their Buy rating on CytomX Therapeutics (NASDAQ:CTMX) and set a $16 price target. T…
CytomX Therapeutics, Inc. (NASDAQ:CTMX) earns a spot on our list of the best penny stocks set to explode.Analysts Bullish on CytomX Therapeutics (CTMX) As CTMX Prices $250 Million Offering As of April 8, 2026, all covering analysts rate Cy…
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best multibagger penny stocks to invest in. On March 23, analysts at Piper Sandler reiterated an Overweight rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) and increased the price tar…
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, region…
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the popular penny stocks on Robinhood to buy. On March 23, Piper Sandler analyst Joseph Catanzaro raised his price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $12 from $10, while m…
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 11 Most Active Small Cap Stocks to Buy. On March 18, CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw Jefferies raise its price target to $16 from $8 while maintaining a Buy rating following…
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 1.6% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
(RTTNews) - CytomX Therapeutics, Inc.(CTMX), a clinical-stage, oncology-focused biopharmaceutical company, announced the pricing of a public offering of 45.99 million shares at a price to the public of $5.30 per share and pre-funded warran…
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of…
Shares of CytomX Therapeutics CTMX soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line metastatic colorectal cancer (CRC) fro…
(RTTNews) - CytomX Therapeutics, Inc. (CTMX), a clinical-stage, oncology-focused biopharmaceutical company, announced that it has commenced an underwritten public offering of $250.0 million of shares and pre-funded warrants. CytomX expects…
CytomX Therapeutics(NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorect…
CytomX Therapeutics(NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorect…
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Salesforce To Purchase Popular Messaging Platform Slack For 27 Billion] Stephen Lam/Getty Images News J.P. Morgan’s equity derivatives team, led by strategist Bram Kaplan, favors selling puts as a target-buy strategy on oversold, high-qua…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change HCW Biologics Inc. 179,323,336 1.10 0.6775 1.03 +0.5139 Cytomx Therapeutic…
(RTTNews) - CytomX Therapeutics, Inc. (CTMX) reported new positive clinical data for its lead antibody-drug conjugate, Varsetatug masetecan (Varseta-M), alongside its full-year 2025 financial results, underscoring continued progress across…
Major earnings expected before the bell on Monday include: * Dollar Tree (DLTR [https://seekingalpha.com/symbol/DLTR]) * Agenus (AGEN [https://seekingalpha.com/symbol/AGEN]) * CytomX Therapeutics (CTMX [https://seekingalpha.com/symbol/CTMX…
Information technology, industrials and utilities are set to feature prominently in this week’s earnings calendar, with 249 companies scheduled to report. This week’s quant rankings highlight strong momentum among technology and industrial…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CytomX Therapeutics is back in focus after recent Street research clustered around higher price t…
NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. This quart…
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 15 Best Small Cap Stocks to Buy According to Wall Street.Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating On February 4, 202…
Qiagen (QGEN) came out with quarterly earnings of $0.62 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items. This quarterly repo…
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The eighth stock on our list of best biotech stocks under $20 is CytomX Therapeutics, Inc. TheFly reported on January 20 that Piper Sandler raised its price ta…
Qiagen QGEN shares soared 16.6% in the last trading session to close at $55.45. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.9% loss over the past four wee…